SEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)

$CINC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CINC alert in real time by email
SC TO-T/A 1 tm232683d9_sctot.htm SC TO-T

 

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

SCHEDULE TO
(Rule 14d-100)

 

TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE
ACT OF 1934

Amendment No. 2

 

 

 

CINCOR PHARMA, INC.
(Name of Subject Company (Issuer))

 

CINNAMON ACQUISITION, INC.

a wholly owned subsidiary of

 

ASTRAZENECA FINANCE AND HOLDINGS INC.

a wholly owned subsidiary of

 

ASTRAZENECA PLC

(Names of Filing Persons — Offerors)

 

 

 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

 

17240Y109
(CUSIP Number of Class of Securities (Underlying Common Stock))

 

Adrian Kemp

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

England

Telephone: +44 20 3749 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

 

Copies to:

Michael J. Riella, Esq.

Covington & Burling LLP

One CityCenter

850 Tenth Street, NW

Washington, DC 20001-4956

+1 (202) 662 6000

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

Amount Previously Paid:   $158,137   Filing party:   Cinnamon Acquisition, Inc., AstraZeneca Finance and Holdings Inc. and AstraZeneca Plc
Form or Registration No.:   Schedule TO   Date filed:   January 23, 2023

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

  x Third-party tender offer subject to Rule 14d-1.
  ¨ Issuer tender offer subject to Rule 13e-4.
  o Going-private transaction subject to Rule 13e-3.
  o Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

  o Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  o Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

 

 

 

This Amendment No. 2 (this “Amendment No. 2”) amends and supplements the Tender Offer Statement on Schedule TO (as further amended or supplemented from time to time, the “Schedule TO”) filed with the Securities and Exchange Commission on January 23, 2023, by AstraZeneca PLC, a public limited company incorporated in England and Wales (“AstraZeneca”), AstraZeneca Finance and Holdings Inc., a Delaware corporation and direct wholly owned subsidiary of AstraZeneca (“Parent”), and Cinnamon Acquisition, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“Purchaser”). The Schedule TO relates to the offer by Purchaser, pursuant to the terms and subject to the conditions of an Agreement and Plan of Merger, dated as of January 8, 2023 (the “Merger Agreement”), by and among CinCor Pharma, Inc., a Delaware corporation (“CinCor”), Parent and Purchaser to purchase all of the outstanding shares of common stock, $0.00001 par value per share (the “Shares”), of CinCor in exchange for (i) $26.00 per Share in cash, plus (ii) one contingent value right per Share representing the right to receive a contingent payment of $10.00 in cash if a specified milestone is achieved, subject to and in accordance with the terms of the Contingent Value Rights Agreement in the form attached as Exhibit E to the Merger Agreement, in each case, without interest, subject to any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase and in the related Letter of Transmittal, copies of which are attached to the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.

 

Except as otherwise set forth in this Amendment No. 2, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 2. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO.

 

Item 11

 

1.The disclosure in the Offer to Purchase and Item 11 of the Schedule TO is hereby amended and supplemented by adding the following sentence at the end of the last paragraph at the end of Section 16—“Certain Legal Matters; Regulatory Approvals—Antitrust Compliance” of the Offer to Purchase on page 59.

 

“The waiting period under the HSR Act expired on February 22, 2023, at 11:59 p.m., Eastern Time. Accordingly, the condition to the Offer requiring that the waiting period (or any extension thereof) applicable to the Offer under the HSR Act shall have expired or been terminated has been satisfied. The Offer continues to be subject to the remaining conditions set forth in the Offer to Purchase.”

 

 

 

 

SIGNATURES

 

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

     
  ASTRAZENECA PLC
     
  By:

/s/ Adrian Kemp

    Name: Adrian Kemp
    Title: Company Secretary
   
  ASTRAZENECA FINANCE AND HOLDINGS INC.
     
  By:

/s/ David White

    Name: David White
    Title: Treasurer
   
  CINNAMON ACQUISITION, INC.
     
  By: /s/ David White
    Name: David White
    Title: Treasurer

 

Date: February 23, 2023

 

 

Get the next $CINC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CINC

DatePrice TargetRatingAnalyst
12/7/2022$22.00Overweight
Barclays
11/29/2022Outperform → Perform
Oppenheimer
11/29/2022$60.00 → $22.00Overweight → Equal-Weight
Morgan Stanley
10/28/2022$67.00Buy
Goldman
8/22/2022$73.00Overweight
Piper Sandler
2/1/2022Outperform
Evercore ISI
2/1/2022$30.00Outperform
Oppenheimer
2/1/2022$27.00Overweight
Morgan Stanley
More analyst ratings

$CINC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Axonis Therapeutics Announces $115 Million Series A Financing

    -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

    - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

    $AKRO
    $APLS
    $AUPH
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Specialty Chemicals
    Consumer Durables
  • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

    Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

    $IMPL
    $CINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CINC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CINC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CINC
SEC Filings

See more

$CINC
Financials

Live finance-specific insights

See more
  • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

    Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

    $IMPL
    $CINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

    Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension population (nominal p-value = 0.001) Safety profile and tolerability consistent with BrigHtn Phase 2 data; no patient discontinued due to treatment-related adverse events; low hyperkalemia incidence HALO in combination with BrigHtn informs the dose and study populations anticipated to be recruited into Phase 3 trials pending confirmation by FDA at planned end of Phase 2 meeting in January 2023; Phase 3 trials expec

    $CINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

    Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline at the 2 mg dose Well-tolerated profile and differentiated mechanism of action supports combination approaches Conference call and live webcast Tuesday November 8th, 2022 at 7 AM Eastern Time WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart A

    $CINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CINC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more